HRP20190289T1 - Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba - Google Patents

Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba

Info

Publication number
HRP20190289T1
HRP20190289T1 HRP20190289TT HRP20190289T HRP20190289T1 HR P20190289 T1 HRP20190289 T1 HR P20190289T1 HR P20190289T T HRP20190289T T HR P20190289TT HR P20190289 T HRP20190289 T HR P20190289T HR P20190289 T1 HRP20190289 T1 HR P20190289T1
Authority
HR
Croatia
Prior art keywords
stemic
antigenes
prostate
stations
specific
Prior art date
Application number
HRP20190289TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael Bachmann
Original Assignee
Gemoab Monoclonals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemoab Monoclonals Gmbh filed Critical Gemoab Monoclonals Gmbh
Publication of HRP20190289T1 publication Critical patent/HRP20190289T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HRP20190289TT 2011-06-30 2012-06-29 Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba HRP20190289T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
EP12729996.4A EP2726507B1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
PCT/EP2012/062716 WO2013001065A1 (de) 2011-06-30 2012-06-29 Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung

Publications (1)

Publication Number Publication Date
HRP20190289T1 true HRP20190289T1 (hr) 2019-05-03

Family

ID=46384405

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190289TT HRP20190289T1 (hr) 2011-06-30 2012-06-29 Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba

Country Status (18)

Country Link
US (1) US9200078B2 (OSRAM)
EP (2) EP3505536B1 (OSRAM)
JP (4) JP2014528696A (OSRAM)
AU (1) AU2012277784B2 (OSRAM)
CY (1) CY1121249T1 (OSRAM)
DE (1) DE102011118022B4 (OSRAM)
DK (1) DK2726507T3 (OSRAM)
ES (2) ES2989975T3 (OSRAM)
HR (1) HRP20190289T1 (OSRAM)
HU (1) HUE042008T2 (OSRAM)
LT (1) LT2726507T (OSRAM)
PL (1) PL2726507T3 (OSRAM)
PT (1) PT2726507T (OSRAM)
RS (1) RS58448B1 (OSRAM)
SI (1) SI2726507T1 (OSRAM)
SM (1) SMT201900085T1 (OSRAM)
TR (1) TR201901991T4 (OSRAM)
WO (1) WO2013001065A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
AU2021276327A1 (en) * 2020-05-19 2022-12-01 City Of Hope Engineered anti-prostate stem cell antigen fusion proteins and uses thereof
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
WO1998040403A1 (en) * 1997-03-10 1998-09-17 The Regents Of The University Of California Psca: prostate stem cell antigen
DK1226177T3 (da) * 1999-10-29 2008-10-06 Genentech Inc Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf
KR101229731B1 (ko) * 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
JP4651663B2 (ja) * 2004-05-28 2011-03-16 アジェンシス，インコーポレイテッド Ｐｓｃａタンパク質に結合する抗体および関連分子
CA2698343C (en) * 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
BRPI0919840B1 (pt) * 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Also Published As

Publication number Publication date
RS58448B1 (sr) 2019-04-30
PL2726507T3 (pl) 2019-06-28
ES2711978T3 (es) 2019-05-08
JP6886491B2 (ja) 2021-06-16
LT2726507T (lt) 2019-04-10
US20140134155A1 (en) 2014-05-15
JP2021121201A (ja) 2021-08-26
AU2012277784B2 (en) 2015-08-20
SI2726507T1 (sl) 2019-05-31
EP2726507B1 (de) 2018-11-21
DE102011118022B4 (de) 2018-01-18
JP2014528696A (ja) 2014-10-30
EP3505536A1 (de) 2019-07-03
ES2989975T3 (es) 2024-11-28
DE102011118022A1 (de) 2013-01-03
DK2726507T3 (en) 2019-03-11
WO2013001065A1 (de) 2013-01-03
US9200078B2 (en) 2015-12-01
JP7341185B2 (ja) 2023-09-08
JP6549622B2 (ja) 2019-07-24
PT2726507T (pt) 2019-02-26
HUE042008T2 (hu) 2019-06-28
EP3505536B1 (de) 2024-08-07
AU2012277784A1 (en) 2014-02-06
TR201901991T4 (tr) 2019-03-21
CY1121249T1 (el) 2020-05-29
EP2726507A1 (de) 2014-05-07
EP3505536C0 (de) 2024-08-07
JP2019193652A (ja) 2019-11-07
JP2017104113A (ja) 2017-06-15
SMT201900085T1 (it) 2019-05-10

Similar Documents

Publication Publication Date Title
HRP20190289T1 (hr) Protutijela protiv antigena specifičnog za matične stanice prostate i njihova upotreba
SI2683406T1 (sl) Protitelesa ANTI-CD40 in njihova uporaba
IL231777B (en) Antibodies against tl1a and uses thereof
HRP20181515T1 (hr) Mezenhimne stromalne stanice i upotreba povezana s njima
IL231282A0 (en) Antibodies to 9pcsk and their uses
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
SI2970456T1 (sl) Postopki in sestavki za dostavo MRNA-kodiranih protiteles
PL3863288T3 (pl) Sposoby intra-predykcji i środek nośnikowy
SI2812443T1 (sl) Protitelesa CD47 in postopki za njihovo uporabo
ME03440B (me) Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
HRP20182098T1 (hr) Anti-angptl3 antitijela i njihove primjene
HRP20170713T1 (hr) Bispecifično anti-igf-1r i anti-erbb3 antitijelo
PL2731677T3 (pl) Przeciwciała wiążące się z OX40 i ich zastosowania
PL2888284T3 (pl) Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
EP2761554A4 (en) PAYMENTS IN SOCIAL PROXIMITY
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
EP2888593A4 (en) ANTIBODY AGAINST RISPERIDONE AND USE THEREOF
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
BR112014013034A2 (pt) método para produzir um anticorpo
PL2887952T3 (pl) Przeciwciała przeciwko haptenom olanzapinowym i ich zastosowanie
BR112014002716A2 (pt) anticorpos anti-poliubiquitina e métodos de uso
BR112014008691A2 (pt) anticorpos para cd1d
FI20116306L (fi) Teroitin
HUE037212T2 (hu) Anti-alfa-V integrin ellenanyag prosztatarák kezelésére